SCHEMBL25222870

SCHEMBL25222870

CC(C)(C)OC(=O)Cn1cnc2c(NCCNC(=O)OC(C)(C)C)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNE2 O96020 1/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ TMIGD3 P0DMS9 3/20 0.41
▸ ADORA2A P29274 3/20 0.41
▸ ADORA1 P30542 3/20 0.41
▸ HTT P42858 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ HDAC1 Q13547 5/20 0.40
▸ HDAC2 Q92769 5/20 0.40
▸ DOT1L Q8TEK3 1/20 0.40
▸ STK17B O94768 1/20 0.40
▸ STK17A Q9UEE5 1/20 0.40
▸ LATS1 O95835 1/20 0.38
▸ OPRM1 P35372 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ OGFRL1 Q5TC84 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23885300 0.92 TMIGD3 (0.43) BRD4TMIGD3ADORA2AADORA1HTT
SCHEMBL30052380 0.92 TMIGD3 (0.43) BRD4TMIGD3ADORA2AADORA1HTT
SCHEMBL30254310 0.89 PDE4A (0.40) BRD4TMIGD3ADORA2AADORA1ADORA2B
SCHEMBL18176944 0.85 ADORA2A (0.43) BRD4TMIGD3ADORA2AADORA1HTT
SCHEMBL18176940 0.85 ADORA2A (0.48) BRD4TMIGD3ADORA2AADORA1ADORA2B
SCHEMBL18176935 0.84 TMIGD3 (0.41) BRD4TMIGD3ADORA2AADORA1HTT
SCHEMBL18179481 0.82 TMIGD3 (0.41) BRD4TMIGD3ADORA2AADORA1HTT
SCHEMBL18176939 0.79 TMIGD3 (0.44) CDK2BRD4TMIGD3ADORA2AADORA1
SCHEMBL24540240 0.77 TDP1 (0.42) TDP1HDAC1HDAC2
SCHEMBL26230949 0.76 FLT4 (0.49) CCNE2CCNE1CDK2TMIGD3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP CCNE2 2276/4885CCNE1 1662/4885CDK2 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback